title: Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1.
abstract: Vaccination of mice with the leading malaria vaccine candidate homologue, the 19-kDa carboxyl terminus of merozoite surface protein-1 (MSP119), results in sterile immunity to Plasmodium yoelii, with no parasites detected in blood. Although such immunity depends upon high titer Abs at challenge, high doses of immune sera transferred into naive mice reduce parasitemia (and protect from death) but do not result in a similar degree of protection (with most mice experiencing high peak parasitemias); this finding suggests that ongoing parasite-specific immune responses postchallenge are essential. We analyzed this postchallenge response by transferring Abs into manipulated but malaria-naive mice and observed that Abs cannot protect SCID, nude, CD4+ T cell-depleted, or B cell knockout mice, with all mice dying. Thus, in addition to the Abs that develop following MSP119 vaccination, a continuing active immune response postchallenge is required for protection. MSP119-specific Abs can adoptively transfer protection to strains of mice that are not protected following vaccination with MSP119, suggesting that the Ags targeted by the immune response postchallenge include Ags apart from MSP119. These data have important implications for the development of a human malaria vaccine.
authors.affiliation: Queensland Institute of Medical Research, Brisbane, Australia.
authors.forename: C
authors.initials: C
authors.lastname: Hirunpetcharat
authors.forename: P
authors.initials: P
authors.lastname: Vukovic
authors.forename: X Q
authors.initials: XQ
authors.lastname: Liu
authors.forename: D C
authors.initials: DC
authors.lastname: Kaslow
authors.forename: L H
authors.initials: LH
authors.lastname: Miller
authors.forename: M F
authors.initials: MF
authors.lastname: Good
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000008:administration & dosage* / Q000627:therapeutic use; D000918:Antibody Specificity; D001402:B-Lymphocytes / Q000276:immunology* / Q000378:metabolism / Q000469:parasitology; D007110:Immunity, Active; D007116:Immunization, Passive; D007274:Injections, Intraperitoneal; D008288:Malaria / Q000276:immunology* / Q000469:parasitology / Q000517:prevention & control; D017780:Malaria Vaccines / Q000276:immunology; D020066:Merozoite Surface Protein 1 / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D008819:Mice, Nude; D016513:Mice, SCID; D008970:Molecular Weight; D010446:Peptide Fragments / Q000276:immunology*; D010967:Plasmodium yoelii / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology* / Q000378:metabolism / Q000469:parasitology
chemical_list: D000913:Antibodies, Protozoan; D017780:Malaria Vaccines; D020066:Merozoite Surface Protein 1; D010446:Peptide Fragments